Medimaps Breaks New Ground in Fracture Risk Assessment with FDA Clearance and MDR Certification for TBS Osteo Next Generation Software
27/09/2024 -
Media - Press releases
Award-winning study confirms Medimaps Group new AI software accurately assesses bone fragility from routine X-rays
04/09/2023 -
Press releases
Medimaps Group receives EU certification under the medical device regulation
05/07/2023 -
Press releases
Medimaps Group deep-tech TBS software endorsed by international experts working group to inform osteoporosis management decisions for the benefit of the patient
01/03/2023 -
Press releases
Medimaps Group presents data showing new AI approach enhances osteoporosis diagnosis and monitoring at ECR 2023
28/11/2022 -
Press releases
Medimaps Group appoints Meinhard F. Schmidt as Board Chairman; adds Anne Le Grand and five additional board members
14/11/2022 -
Press releases
Medimaps Group announces partnership with OsteoSys to bring trabecular bone score to Korea’s leading bone densitometry platform
04/03/2022 -
Press releases
Medical reimbursement now available for trabecular bone score (TBS), an advanced medtech solution with artificial intelligence capabilities, for osteoporosis fracture risk assessment
01/01/2021 -
Press releases
Medimaps Group raises $20 million to expand and to commercialize AI product portfolio for bone health assessment utilizing routine medical images
medimaps group SA
Chemin du Champ-des-Filles 36A
1228 Plan-les-Ouates
Geneva, Switzerland
Medimaps Group USA LLC
1201N Market Street
Suite 111
Wilmington, DE 19801, United States
Medimaps Group has been certified by BSI to ISO 13485:2016 under certificate number MDR 799726. TBS iNsight is a trademark of Medimaps Group. TBS iNsight™ is cleared for sale in the U.S.
Please note that you are now accessing content reserved for healthcare professionals only. By accepting, you confirm that you are a healthcare professional.
Click “OK” to confirm you are a Healthcare Professional.